基线影像组学特征预测非小细胞肺癌患者总生存期
研究利用CheckMate-017、-026和-063中接受纳武利尤单抗或化疗的NSCLC患者基线CT图像,开发并验证影像组学特征。基于758例患者图像提取38个影像组学变量,构建输出0到1连续值的特征;以0.55为阈值预测3个月OS的敏感性和特异性分别为86%和77.8%,该特征与纳武利尤单抗或化疗患者OS显著相关(p<0.0001)。
要点
- 基线影像组学特征由空间相关性、肝脏肿瘤体积和纵隔淋巴结肿瘤体积组合输出0到1连续值。
- 以0.55为阈值,该特征预测3个月OS的敏感性为86%、特异性为77.8%。
- 该特征在纳武利尤单抗或化疗患者中与OS显著相关(p<0.0001)。
核心结论
- 影像组学特征可提供纳武利尤单抗或化疗NSCLC患者预期OS的早期读数,可能为临床试验中的风险分层提供预后信息。
研究设计与样本
- 影像组学特征在CheckMate-017、-026和-063中接受纳武利尤单抗治疗的NSCLC患者中开发。
- 纳武利尤单抗治疗患者汇总后按2:1:1比例随机分为训练集、校准集或验证集。
- 从基线CT图像半自动分割肿瘤病灶体积,并提取38个描绘肿瘤表型的影像组学变量。
- 在纳武利尤单抗治疗(验证集)和化疗治疗(测试集)患者中评估影像组学特征与OS的关联。
- 基线影像组学特征使用758例患者的CT图像识别。
主要发现
- 影像组学特征组合空间相关性、肝脏肿瘤体积和纵隔淋巴结肿瘤体积等影像变量,输出0到1连续值(0为最有利估计OS,1为最不利估计OS)。
- 以0.55为阈值,影像组学特征预测3个月OS的敏感性为86%,特异性为77.8%。
- 该特征在纳武利尤单抗治疗训练集中识别,并在纳武利尤单抗或化疗治疗患者中与OS显著相关(p<0.0001)。
关键数值与推荐
- 影像组学特征输出0到1连续值,0代表最有利估计OS,1代表最不利估计OS。
- 预测3个月OS的阈值为0.55,敏感性86%,特异性77.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to define a baseline radiomic signature associated with overall survival (OS) using baseline computed tomography (CT) images obtained from patients with NSCLC treated with nivolumab or chemotherapy. METHODS: The radiomic signature was developed in patients with NSCLC treated with nivolumab in CheckMate-017, -026, and -063. Nivolumab-treated patients were pooled and randomized to training, calibration, or validation sets using a 2:1:1 ratio. From baseline CT images, volume of tumor lesions was semiautomatically segmented, and 38 radiomic variables depicting tumor phenotype were extracted. Association between the radiomic signature and OS was assessed in the nivolumab-treated (validation set) and chemotherapy-treated (test set) patients in these studies. RESULTS: A baseline radiomic signature was identified using CT images obtained from 758 patients. The radiomic signature used a combination of imaging variables (spatial correlation, tumor volume in the liver, and tumor volume in the mediastinal lymph nodes) to output a continuous value, ranging from 0 to 1 (from most to least favorable estimated OS). Given a threshold of 0.55, the sensitivity and specificity of the radiomic signature for predicting 3-month OS were 86% and 77.8%, respectively. The signature was identified in the training set of patients treated with nivolumab and was significantly associated (p < 0.0001) with OS in patients treated with nivolumab or chemotherapy. CONCLUSIONS: The radiomic signature provides an early readout of the anticipated OS in patients with NSCLC treated with nivolumab or chemotherapy. This could provide important prognostic information and may support risk stratification in clinical trials.
引用
- Dercle L, Fronheiser M, Rizvi NA, et al. Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. J Thorac Oncol. 2023. PMID: 36646209. doi:10.1016/j.jtho.2022.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。